Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07412704 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Not yet
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT07412704 is a Phase 1 study that has not yet begun recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 84 participants.
The verdict
NCT07412704, a Phase 1 study, has not yet begun recruiting, sponsored by Bristol-Myers Squibb.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).
Interventions
- DRUG BMS-986528
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2030-09-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07412704
The ClinicalTrials.gov registry entry for NCT07412704 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-986528 is the first listed.
NCT07412704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07412704 about?
NCT07412704 is a clinical study titled "A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).
What is the current status of trial NCT07412704?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2026-05-28. Estimated completion is 2030-09-02.
What interventions are being tested in trial NCT07412704?
The interventions under investigation include: BMS-986528 (DRUG).
Who is sponsoring clinical trial NCT07412704?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.